Filing Details

Accession Number:
0001209191-18-052368
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-09-26 19:00:17
Reporting Period:
2018-09-24
Accepted Time:
2018-09-26 19:00:17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1628738 Audentes Therapeutics Inc. BOLD () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1238401 G Louis Lange C/O Audentes Therapeutics, Inc.
600 California Street, 17Th Floor
San Francisco CA 94108
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2018-09-24 19,800 $37.35 365,999 No 4 S Direct
Common Stock Disposition 2018-09-24 200 $37.76 365,799 No 4 S Direct
Common Stock Disposition 2018-09-24 1,000 $37.25 7,555 No 4 S Indirect By Adrienne M. MacMillan Revocable Trust
Common Stock Disposition 2018-09-24 1,000 $37.27 18,678 No 4 S Indirect By Amygdala Lange Trust
Common Stock Disposition 2018-09-24 1,000 $37.27 1,558 No 4 S Indirect By Lange Minor's Trust
Common Stock Disposition 2018-09-24 10,000 $37.45 42,343 No 4 S Indirect By Asset Management Ventures Fund, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Indirect By Adrienne M. MacMillan Revocable Trust
No 4 S Indirect By Amygdala Lange Trust
No 4 S Indirect By Lange Minor's Trust
No 4 S Indirect By Asset Management Ventures Fund, L.P.
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. Represents the weighted average sale price. The lowest price at which shares were sold was $36.72 and the highest price at which shares were sold was $37.71. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (6) and (9) to this Form 4.
  3. Represents the weighted average sale price. The lowest price at which shares were sold was $37.75 and the highest price at which shares were sold was $37.76.
  4. Represents the weighted average sale price. The lowest price at which shares were sold was $36.84 and the highest price at which shares were sold was $37.61.
  5. The reporting person's spouse is the trustee of the Adrienne M. MacMillan Revocable Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
  6. Represents the weighted average sale price. The lowest price at which shares were sold was $36.93 and the highest price at which shares were sold was $37.62.
  7. The reporting person's spouse is the trustee of the Amygdala Lange Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
  8. The reporting person's spouse is the trustee of the Lange Minor's Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
  9. Represents the weighted average sale price. The lowest price at which shares were sold was $37.00 and the highest price at which shares were sold was $37.675.
  10. The reporting person is a general partner of Asset Management Ventures Fund, L.P. ("AMVF L.L.P."), and has shared voting and dispositive power over the shares held by AMVF L.L.P. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.